Short Interest in Vor Biopharma Inc. (NASDAQ:VOR) Drops By 94.4%

Key Points

• Short interest in Vor Biopharma Inc. significantly dropped by 94.4% in September, decreasing from 19,780,000 shares to 1,100,000 shares.
• The company's stock is currently priced at $48.49, following a recent trading spike, and has a market cap of $332.16 million.
• Recent analyst ratings for Vor Biopharma have varied, with Zacks Research upgrading the stock to a "hold" while HC Wainwright gave it a "strong-buy" rating.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 1,100,000 shares, a decrease of 94.4% from the August 31st total of 19,780,000 shares. Approximately 27.9% of the shares of the stock are sold short. Based on an average daily volume of 909,000 shares, the days-to-cover ratio is currently 1.2 days. Based on an average daily volume of 909,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 27.9% of the shares of the stock are sold short.

Vor Biopharma Stock Performance

Shares of VOR stock traded up $8.60 on Tuesday, hitting $48.49. The company had a trading volume of 555,431 shares, compared to its average volume of 381,949. The company's 50-day moving average price is $39.04. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The stock has a market cap of $332.16 million, a price-to-earnings ratio of -0.18 and a beta of 2.05.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Analyst Ratings Changes

Several research firms have recently issued reports on VOR. Zacks Research raised Vor Biopharma from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 10th. HC Wainwright raised Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. Finally, Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy".

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.